Bharat Biotech on Monday said it has begun the phase 3 clinical trials of its coronavirus disease (Covid-19) vaccine candidate, Covaxin, in India, with 26,000 participants across 22 sites in the country. The trial will be conducted in partnership with…
Read More
Feluda, the cheaper CRISPR based Covid test launched by Tata group
Tata Medical and Diagnostics Ltd. (TataMD), the healthcare venture of the Tata Group, on Monday announced the launch of ‘TataMD’s CHECK’, which is the gene-editing technology CRISPR based test for coronavirus disease (Covid-19) developed by the researchers from the CSIR-Institute…
Read More